Search Results

Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, is pleased to announce that it has entered into an agreement to acquire the European rights to Duphaston® and Femoston® from Viatris Inc.

Donaldson Company, Inc., a leading worldwide provider of innovative filtration products and solutions, announced it has entered into a definitive agreement allowing the Company to purchase a 49% stake in Medica S.p.A.

Enovis™ Corporation an innovation-driven, medical technology growth company, announced that it closed the acquisition of LimaCorporate S.p.A., a privately held global orthopedic leader focused on restoring motion through an innovative portfolio of implant solutions.

Nemysis is pleased to announce that it has entered into a Strategic Alliance Agreement with Bruno Farmaceutici S.p.A. for the mutual advancement of the portfolio and sales of each company.

Quince Therapeutics, Inc. announced the successful completion of its acquisition of EryDel S.p.A., a privately-held, late-stage biotech company.

Axxam S.p.A. and Momentum Biotechnologies have announced a partnership to provide unique drug discovery solutions for biotechnology and pharmaceutical clients.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) today announced that the U.S. Food and Drug Administration (FDA) has agreed to a Special Protocol Assessment (SPA) Agreement Modification for the Company’s pivotal Phase 3 SOL clinical trial of AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degeneration (wet AMD).

Outlook Therapeutics, Inc. today announced that, following receipt of written confirmation of the NORSE EIGHT proposed clinical trial protocol with the U.S. Food and Drug Administration (FDA), Outlook Therapeutics has submitted a Special Protocol Assessment (SPA) request for the required additional adequate and well-controlled study of ONS-5010.

Tarsier Pharma, Ltd. today announced it has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA).